title: Single-nucleotide polymorphisms in the P2X7 receptor gene are associated with post-menopausal bone loss and vertebral fractures.
abstract: The purinergic P2X7 receptor has a major role in the regulation of osteoblast and osteoclast activity and changes in receptor function may therefore affect bone mass in vivo. The aim of this study was to determine the association of non-synonymous single-nucleotide polymorphisms in the P2RX7 gene to bone mass and fracture incidence in post-menopausal women. A total of 1694 women (aged 45-58) participating in the Danish Osteoporosis Prevention Study were genotyped for 12 functional P2X7 receptor variants. Bone mineral density was determined at baseline and after 10 years. In addition, vertebral fracture incidence was documented at 10 years. We found that the rate of bone loss was clearly associated with the Arg307Gln amino acid substitution such that individuals heterozygous for this polymorphism had a 40% increased rate of bone loss. Furthermore, individuals carrying the Ile568Asn variant allele had increased bone loss. In contrast, the Gln460Arg polymorphism was associated with protection against bone loss. The Ala348Thr polymorphism was associated with a lower vertebral fracture incidence 10 years after menopause. Finally, we developed a risk model, which integrated P2RX7 genotypes. Using this model, we found a clear association between the low-risk (high-P2X7 function) alleles and low rate of bone loss. Conversely, high-risk (reduced P2X7 function) alleles were associated with a high rate of bone loss. In conclusion, an association was demonstrated between variants that reduce P2X7 receptor function and increased rate of bone loss. These data support that the P2X7 receptor is important in regulation of bone mass.
authors.affiliation: Research Center for Ageing and Osteoporosis, Department of Clinical Biochemistry, Glostrup University Hospital, Glostrup, Denmark. niklas@dadlnet.dk
authors.forename: Niklas R
authors.initials: NR
authors.lastname: Jørgensen
authors.forename: Lise B
authors.initials: LB
authors.lastname: Husted
authors.forename: Kristen K
authors.initials: KK
authors.lastname: Skarratt
authors.forename: Leanne
authors.initials: L
authors.lastname: Stokes
authors.forename: Charlotte L
authors.initials: CL
authors.lastname: Tofteng
authors.forename: Torben
authors.initials: T
authors.lastname: Kvist
authors.forename: Jens-Erik B
authors.initials: JE
authors.lastname: Jensen
authors.forename: Pia
authors.initials: P
authors.lastname: Eiken
authors.forename: Kim
authors.initials: K
authors.lastname: Brixen
authors.forename: Stephen
authors.initials: S
authors.lastname: Fuller
authors.forename: Rory
authors.initials: R
authors.lastname: Clifton-Bligh
authors.forename: Alison
authors.initials: A
authors.lastname: Gartland
authors.forename: Peter
authors.initials: P
authors.lastname: Schwarz
authors.forename: Bente L
authors.initials: BL
authors.lastname: Langdahl
authors.forename: James S
authors.initials: JS
authors.lastname: Wiley
mesh_terms: D015519:Bone Density / Q000235:genetics; D005260:Female; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide; D017698:Postmenopause / Q000235:genetics*; D058486:Receptors, Purinergic P2X7 / Q000235:genetics*; D016103:Spinal Fractures / Q000209:etiology / Q000235:genetics* / Q000378:metabolism
chemical_list: D058486:Receptors, Purinergic P2X7